Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693895 · ClinicalTrials.gov registry record · Phase 3
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
A Phase 3 study of Chickenpox, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 1
- Study location
NCT06693895: Recruiting Phase 3 study of Chickenpox, sponsored by GlaxoSmithKline.
NCT06693895 is a Phase 3 study of Chickenpox that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 750 participants, above the 571-participant average among 5 other Chickenpox trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693895, a Phase 3 study of Chickenpox, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
Primary Outcome
Solicited administration site events include injection site redness, pain and swelling.
Conditions Studied
Interventions
- BIOLOGICAL Marketed varicella vaccine
- BIOLOGICAL Hepatitis A vaccine
- BIOLOGICAL PCV (pneumococcal conjugate vaccine) 13
- BIOLOGICAL Investigational varicella vaccine
- BIOLOGICAL Measles, mumps, and rubella vaccine
Study Locations (1)
California
- GSK Investigational Site - West Covina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-11-23 |
| Phase | Phase 3 |
What NCT06693895 shows while recruiting
NCT06693895 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 571-participant average among 5 other Chickenpox trials with a reported enrollment target (31% higher).
The record links to 1 condition, with Chickenpox appearing as the primary indexed condition, and to 5 interventions - of which Marketed varicella vaccine is the first listed.
NCT06693895 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06693895 about?
NCT06693895 is a clinical study titled "A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age". The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted vari...
What is the current status of trial NCT06693895?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2024-11-26. Estimated completion is 2026-11-23.
What conditions does trial NCT06693895 study?
This clinical trial studies the following conditions: Chickenpox.
What interventions are being tested in trial NCT06693895?
The interventions under investigation include: Marketed varicella vaccine (BIOLOGICAL), Hepatitis A vaccine (BIOLOGICAL), PCV (pneumococcal conjugate vaccine) 13 (BIOLOGICAL), Investigational varicella vaccine (BIOLOGICAL), Measles, mumps, and rubella vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06693895?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693895 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chickenpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
RECRUITING · Phase 3
-
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
RECRUITING · Phase 3
-
Immune Response to Varicella-Zoster Vaccination and Infection
COMPLETED
-
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
COMPLETED · Phase 1
-
Systems Biology of Zoster Vaccine
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI